Galen Holdings Appoints Senior Executives to Management Team

Apr 11, 2001, 01:00 ET from Galen Holdings PLC

    CRAIGAVON, Northern Ireland and ROCKAWAY, N.J., April 11 /PRNewswire/ --
 Galen Holdings PLC (Nasdaq:   GALN; LSE: GAL), the international specialty
 pharmaceutical company, today announced the appointment of two new senior
 executives to its management team.
     Anthony Bruno will assume the position of Senior Vice President, Business
 Development and General Counsel, responsible for all of Galen's worldwide
 legal affairs as well as business development.  Mr. Bruno enjoyed a successful
 career at Warner-Lambert, now part of Pfizer, for 17 years.  His most recent
 position was Vice President and Associate General Counsel of Pharmaceuticals,
 where he was responsible for all legal matters relating to Warner-Lambert
 Global Pharmaceuticals.
     Frank Ritt will join the team as Senior Vice President, Finance,
 responsible for treasury and tax planning, and a number of related financial
 process projects.  Mr. Ritt also enjoyed a very successful career of over
 20 years at Warner-Lambert.  His most recent position was Vice President,
 Economic Affairs, where he was responsible for transfer pricing and part of
 the corporate financial consolidation process.  Previous to this role he
 served as Vice President and Assistant Treasurer, responsible for
 International Treasury Operations.
     Roger Boissonneault, CEO of Galen, said: "We are pleased to welcome
 high-caliber professionals such as Tony and Frank to Galen's management team.
 With extensive experience within a major pharmaceutical company such as
 Warner-Lambert, the two possess a wide range of skills and experience that
 will be invaluable as we take the company to the next level of growth."
 
     Galen is an integrated specialty pharmaceutical company based in
 Craigavon, Northern Ireland and Rockaway, New Jersey, USA.  Galen develops,
 acquires and manufactures branded pharmaceutical products, which are promoted
 by the company's sales and marketing organizations in the UK, Ireland and the
 US.  Galen's Pharma Services division supplies and distributes clinical trial
 materials internationally, operates a drug reconciliation business and
 provides computer-based interactive voice response systems to permit the
 efficient management of worldwide clinical trials.  The Pharma Services
 division also provides "bench-to-pilot-scale" custom chemical design and
 synthesis services to the research-based pharmaceutical industry.
 
     For further information on Galen, please visit http://www.galenplc.com
 
     Note:
     Statements made in this press release include forward-looking statements
 made pursuant to the safe harbor provisions of the Securities Litigation
 Reform Act of 1995.  Such statements, including those relating to financial
 expectations for the fiscal year 2001 and beyond, involve certain risks and
 uncertainties that could cause actual results to differ materially from those
 in the forward looking statements, including, but not limited to, the
 company's dependence on key products, risks associated with product
 development and manufacturing, the uncertainty of future financial results and
 fluctuations in operating results, dependence on the Company's acquisition
 strategy, new product introductions, currency fluctuations and other risks
 described from time to time in the Company's SEC filings.  These
 forward-looking statements represent the judgment of the Company, as of the
 date of this release, and the Company disclaims any intent or obligation to
 update these forward-looking statements.  Information on other significant
 potential risks and uncertainties not discussed herein may be found in the
 Company's filings with the Securities and Exchange Commission including its
 Form 20F for the year ended September 30, 2000, when filed, and all
 information previously filed by the Company's wholly-owned subsidiary, Warner
 Chilcott plc, including Warner Chilcott plc's definitive proxy statement filed
 with the SEC on August 8, 2000.
 
 

SOURCE Galen Holdings PLC
    CRAIGAVON, Northern Ireland and ROCKAWAY, N.J., April 11 /PRNewswire/ --
 Galen Holdings PLC (Nasdaq:   GALN; LSE: GAL), the international specialty
 pharmaceutical company, today announced the appointment of two new senior
 executives to its management team.
     Anthony Bruno will assume the position of Senior Vice President, Business
 Development and General Counsel, responsible for all of Galen's worldwide
 legal affairs as well as business development.  Mr. Bruno enjoyed a successful
 career at Warner-Lambert, now part of Pfizer, for 17 years.  His most recent
 position was Vice President and Associate General Counsel of Pharmaceuticals,
 where he was responsible for all legal matters relating to Warner-Lambert
 Global Pharmaceuticals.
     Frank Ritt will join the team as Senior Vice President, Finance,
 responsible for treasury and tax planning, and a number of related financial
 process projects.  Mr. Ritt also enjoyed a very successful career of over
 20 years at Warner-Lambert.  His most recent position was Vice President,
 Economic Affairs, where he was responsible for transfer pricing and part of
 the corporate financial consolidation process.  Previous to this role he
 served as Vice President and Assistant Treasurer, responsible for
 International Treasury Operations.
     Roger Boissonneault, CEO of Galen, said: "We are pleased to welcome
 high-caliber professionals such as Tony and Frank to Galen's management team.
 With extensive experience within a major pharmaceutical company such as
 Warner-Lambert, the two possess a wide range of skills and experience that
 will be invaluable as we take the company to the next level of growth."
 
     Galen is an integrated specialty pharmaceutical company based in
 Craigavon, Northern Ireland and Rockaway, New Jersey, USA.  Galen develops,
 acquires and manufactures branded pharmaceutical products, which are promoted
 by the company's sales and marketing organizations in the UK, Ireland and the
 US.  Galen's Pharma Services division supplies and distributes clinical trial
 materials internationally, operates a drug reconciliation business and
 provides computer-based interactive voice response systems to permit the
 efficient management of worldwide clinical trials.  The Pharma Services
 division also provides "bench-to-pilot-scale" custom chemical design and
 synthesis services to the research-based pharmaceutical industry.
 
     For further information on Galen, please visit http://www.galenplc.com
 
     Note:
     Statements made in this press release include forward-looking statements
 made pursuant to the safe harbor provisions of the Securities Litigation
 Reform Act of 1995.  Such statements, including those relating to financial
 expectations for the fiscal year 2001 and beyond, involve certain risks and
 uncertainties that could cause actual results to differ materially from those
 in the forward looking statements, including, but not limited to, the
 company's dependence on key products, risks associated with product
 development and manufacturing, the uncertainty of future financial results and
 fluctuations in operating results, dependence on the Company's acquisition
 strategy, new product introductions, currency fluctuations and other risks
 described from time to time in the Company's SEC filings.  These
 forward-looking statements represent the judgment of the Company, as of the
 date of this release, and the Company disclaims any intent or obligation to
 update these forward-looking statements.  Information on other significant
 potential risks and uncertainties not discussed herein may be found in the
 Company's filings with the Securities and Exchange Commission including its
 Form 20F for the year ended September 30, 2000, when filed, and all
 information previously filed by the Company's wholly-owned subsidiary, Warner
 Chilcott plc, including Warner Chilcott plc's definitive proxy statement filed
 with the SEC on August 8, 2000.
 
 SOURCE  Galen Holdings PLC